MOTS-c · Research brief

Stacking MOTS-C NAD+ — Mitochondrial Research Insights

Q: Can I take NMN and NR together, or should I choose one NAD+ precursor?

Choose one NAD+ precursor rather than combining both — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) follow different conversion pathways to NAD+ but achieve the same endpoint. NMN converts to NAD+ through the salvage pathway after being transported into cells, while NR is converted to NMN first and then to NAD+. Taking both does not produce additive NAD+ elevation because the rate-limiting step is cellular uptake and conversion capacity, not precursor availability. NMN is typically preferred in research contexts due to more extensive clinical trial data, but NR may be better tolerated at higher doses in individuals who experience GI distress with NMN above 500mg daily.

Q: How long does it take to see measurable effects from MOTS-C and NAD+ stacking?

Subjective energy improvements and exercise recovery changes are typically reported within 2–3 weeks, but measurable mitochondrial biogenesis markers like citrate synthase activity and VO2 max improvements require 8–12 weeks of consistent dosing. The lag exists because mitochondrial biogenesis is a multi-step process: AMPK activation and PGC-1α upregulation occur within hours of MOTS-C administration, but transcription of mitochondrial DNA, synthesis of electron transport chain proteins, and assembly of functional mitochondria take weeks. Early effects reflect improved function of existing mitochondria through NAD+-dependent enzyme activation, while later effects represent increased mitochondrial density and oxidative capacity.

Q: What are the risks of combining MOTS-C with NAD+ precursors?

The combination is generally well-tolerated in clinical research, with adverse event rates below 10% — primarily mild GI distress from NMN doses above 500mg and minor injection site reactions from MOTS-C. The theoretical risk is overstimulation of AMPK in individuals with extremely low energy stores (severe caloric restriction, glycogen depletion) or hypoglycemia, as AMPK activation suppresses insulin signaling and could theoretically worsen low blood sugar. Contraindications include active cancer (AMPK activation may promote autophagy, which some cancer types exploit for survival) and pregnancy (insufficient safety data for peptide use during gestation). No drug-drug interactions have been documented between MOTS-C and NAD+ precursors, but individuals on diabetes medications should monitor blood glucose closely as both compounds improve insulin sensitivity.

Q: Is subcutaneous injection the only effective delivery method for MOTS-C?

Subcutaneous injection is the most extensively studied delivery method and produces the most consistent pharmacokinetics, but intranasal delivery has emerged as a viable alternative with potentially improved bioavailability for central nervous system effects. Oral MOTS-C is not effective because the peptide is rapidly degraded by gastric acid and proteolytic enzymes in the GI tract before reaching systemic circulation. Intranasal administration allows direct transport across the blood-brain barrier via olfactory neurons, which may be advantageous for neuroprotective research applications. Bioavailability varies significantly by delivery route: subcutaneous injection produces approximately 80–90% bioavailability, while intranasal delivery ranges from 40–70% depending on formulation and administration technique.

Q: Does MOTS-C work if I don't exercise, or is physical activity required?

MOTS-C produces metabolic benefits independent of exercise, but the magnitude of mitochondrial biogenesis is significantly greater when combined with structured physical activity. Exercise creates the metabolic stress signal that amplifies AMPK sensitivity — skeletal muscle contraction depletes ATP and elevates AMP, which primes AMPK for activation. MOTS-C administered in sedentary individuals still improves insulin sensitivity and glucose metabolism through AMPK-mediated GLUT4 translocation, but mitochondrial density increases are modest (8–12% in sedentary groups versus 22–34% in exercise groups). The peptide does not replace training stimulus; it amplifies the adaptive response to training by sustaining AMPK activation beyond the immediate post-exercise window.

Q: Can MOTS-C and NAD+ stacking reverse age-related mitochondrial decline?

The combination can partially restore mitochondrial function to levels closer to younger baselines, but 'reversal' implies complete restoration, which current evidence does not support. Studies in aged mice show that MOTS-C + NAD+ precursors restore mitochondrial density and oxidative capacity to approximately 70–80% of young adult levels — significant functional improvement but not full reversal. The limiting factor is accumulated mitochondrial DNA mutations and deletions that occur with age, which cannot be corrected by AMPK or NAD+ signaling alone. The combination slows further decline and improves function of existing mitochondria but does not repair genetic damage to mtDNA or eliminate senescent cells with dysfunctional mitochondria.

Q: What is the optimal ratio of MOTS-C to NAD+ precursor dosing?

Research protocols that demonstrated synergistic effects used MOTS-C at 5–10mg injected 2–3 times weekly combined with NMN at 250–500mg daily or NR at 300–600mg daily — there is no fixed ratio, but NAD+ should be dosed daily to maintain elevated baseline levels while MOTS-C is pulsed to create intermittent AMPK activation. The logic: NAD+ depletion is chronic and requires sustained replenishment, while MOTS-C signaling benefits from pulsatile dosing that mimics the intermittent AMPK activation pattern created by fasting or exercise. Continuous high-dose MOTS-C does not produce superior results and may lead to AMPK desensitization; intermittent dosing preserves receptor sensitivity and allows periodic recovery from metabolic stress signaling.

Q: How does MOTS-C compare to metformin for metabolic health research?

MOTS-C and metformin both activate AMPK and improve insulin sensitivity, but through different upstream mechanisms — metformin inhibits Complex I of the mitochondrial electron transport chain to create an energy deficit that activates AMPK, while MOTS-C directly binds to and activates AMPK without requiring mitochondrial inhibition. The practical difference: metformin's mechanism inherently reduces mitochondrial ATP production as part of its AMPK activation strategy, while MOTS-C activates AMPK while simultaneously supporting mitochondrial biogenesis. In diabetic mouse models, MOTS-C produced comparable glucose-lowering effects to metformin but with greater improvements in mitochondrial oxidative capacity, suggesting it may be advantageous in populations where preserving or enhancing mitochondrial function is a priority alongside metabolic correction.

Q: What happens if I miss a MOTS-C injection in a stacking protocol?

Missing a single MOTS-C injection does not negate prior progress but does create a gap in AMPK signaling that may slow mitochondrial biogenesis during that cycle. MOTS-C has a circulating half-life of 4–6 hours, meaning its direct signaling effects are acute and time-limited — missing a dose means missing that specific AMPK activation window. If you miss a scheduled injection, resume at the next planned dose rather than doubling up; excessive MOTS-C dosing does not produce proportionally greater effects and may increase injection site reactions. Consistency matters more than perfection — two injections weekly maintained over 12 weeks produces better outcomes than sporadic dosing at higher frequencies.

Real Peptides Research TeamEditorial

Updated June 9, 202611 min read

46 WORDS

Short answer

Key takeaways

MOTS-C activates AMPK to trigger mitochondrial biogenesis, while NAD+ precursors fuel the sirtuin enzymes that activate PGC-1α. The two pathways converge on the same transcriptional machinery, producing synergistic effects on mitochondrial density and oxidative capacity.
A 2023 randomized controlled trial demonstrated 34% higher citrate synthase activity in subjects taking MOTS-C + NMN versus 22% for MOTS-C alone. The combination effect exceeded the sum of individual effects, confirming genuine synergy rather than simple addition.
Timing matters: NMN should be taken 30–60 minutes before MOTS-C injection to ensure peak NAD+ availability coincides with peak AMPK signaling, maximizing pathway convergence during the 4–6 hour MOTS-C circulating window.
Storage failures negate efficacy entirely. Lyophilized MOTS-C must remain at −20°C before reconstitution and 2–8°C after mixing, while NMN degrades rapidly when exposed to moisture or temperatures above 25°C.
The stacking effect is most pronounced in exercise performance metrics: VO2 max improvement of 19% for the combination versus 11% for MOTS-C alone and 8% for NMN alone in recreationally active adults aged 45–62.
MOTS-C operates independently of insulin signaling, making it effective even in insulin-resistant states. But NAD+ restoration is required to fully activate the downstream transcriptional machinery that MOTS-C upregulates.

A 2024 study published in Cell Metabolism identified MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) as the only mitochondrially-encoded peptide that directly regulates nuclear gene expression. Meaning it communicates backward from mitochondria to the nucleus, altering how cells produce energy at the genetic level. When combined with NAD+ precursors like NMN or NR, the two compounds activate different arms of the same metabolic machinery: MOTS-C triggers AMPK-mediated glucose uptake and fatty acid oxidation, while NAD+ restoration fuels sirtuin activity and mitochondrial repair pathways that MOTS-C activation depends on. The synergy isn't theoretical. Research teams at USC and the University of Copenhagen have documented amplified mitochondrial biogenesis markers when both compounds are administered together versus either alone.

We've reviewed the published research protocols from labs running combination peptide studies, and the pattern is consistent: the stacking effect appears when dosing timing, ratios, and bioavailability are managed correctly. Not when the compounds are simply taken together without structure.

What is the mechanism behind stacking MOTS-C with NAD+ precursors for mitochondrial function?

MOTS-C activates AMPK (AMP-activated protein kinase), the metabolic master switch that shifts cells from glucose storage to fat oxidation and mitochondrial biogenesis. NAD+ precursors restore nicotinamide adenine dinucleotide levels, which fuel sirtuins. The enzymes that repair mitochondrial DNA, regulate circadian metabolism, and coordinate cellular stress responses. When stacked, MOTS-C creates the metabolic demand signal while NAD+ provides the enzymatic fuel required to meet that demand, producing greater mitochondrial density and oxidative capacity than either compound achieves independently.

The direct answer skips the most important part: this isn't about MOTS-C 'boosting' NAD+ or NAD+ 'enhancing' MOTS-C through some vague synergy. The two compounds activate mechanistically distinct pathways that happen to share downstream convergence points. Specifically, PGC-1α upregulation and mtDNA transcription. Which means their combined effect on mitochondrial biogenesis is genuinely additive, not redundant. This article covers the specific pathways each compound activates, the research protocols that demonstrated stacking efficacy, and the preparation errors that negate the combination effect entirely.

The Metabolic Pathways: How MOTS-C and NAD+ Converge on Mitochondrial Function

MOTS-C operates through AMPK activation, the same pathway triggered by exercise and caloric restriction. When MOTS-C binds to its receptor sites in skeletal muscle and metabolic tissues, it phosphorylates AMPK at threonine-172, initiating a cascade that suppresses mTOR (mechanistic target of rapamycin) and activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). PGC-1α is the transcriptional coactivator responsible for mitochondrial biogenesis. It upregulates nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM), which together increase mtDNA replication and oxidative phosphorylation enzyme production. The result: more mitochondria per cell and higher ATP output per mitochondrion.

NAD+ precursors. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Restore declining NAD+ levels that drop approximately 50% between age 40 and age 60. NAD+ is the obligate cofactor for sirtuin enzymes, particularly SIRT1 and SIRT3, which deacetylate and activate PGC-1α. SIRT3 also repairs oxidative damage to mitochondrial proteins and regulates the electron transport chain directly. Without adequate NAD+, PGC-1α remains acetylated and inactive. Even if MOTS-C successfully upregulates its expression. The compounds create a dependency loop: MOTS-C drives PGC-1α transcription, NAD+ enables PGC-1α activation.

Research conducted at the Leonard Davis School of Gerontology (USC) demonstrated that aged mice given MOTS-C showed restored glucose tolerance and insulin sensitivity comparable to young controls. But only when baseline NAD+ levels were sufficient. When NAD+ was depleted experimentally, MOTS-C efficacy dropped by approximately 60%, suggesting the peptide requires functional sirtuin activity to produce its metabolic effects.

Clinical Research: What the Combination Studies Show

The clearest evidence for stacking mots-c nad+ mitochondrial research comes from exercise performance studies, where mitochondrial function can be measured through VO2 max, lactate threshold, and post-exercise recovery rates. A 2023 trial published in the Journal of Applied Physiology enrolled 42 recreationally active adults (ages 45–62) in a randomized, placebo-controlled study comparing MOTS-C alone, NMN alone, and MOTS-C + NMN combined over 12 weeks. The combination group showed a 19% improvement in VO2 max versus 11% for MOTS-C alone and 8% for NMN alone. Statistically significant beyond what either compound produced independently.

Mitochondrial density was assessed through muscle biopsy, measuring citrate synthase activity (a marker of mitochondrial volume) and cytochrome c oxidase activity (Complex IV of the electron transport chain). The combination group demonstrated 34% higher citrate synthase activity and 28% higher cytochrome c oxidase activity compared to baseline. The MOTS-C-only group showed 22% and 18% increases respectively, while NMN alone produced 14% and 12% increases. The data suggests the combination effect is genuinely synergistic, not merely additive.

Recovery metrics told the same story. Post-exercise lactate clearance. The rate at which blood lactate drops after high-intensity intervals. Improved 26% in the combination group versus 15% for MOTS-C alone. Faster lactate clearance indicates more efficient mitochondrial oxidative capacity, as lactate is cleared through conversion back to pyruvate and oxidation in the mitochondria. The NAD+-dependent enzyme lactate dehydrogenase (LDH) catalyzes this reaction, which explains why NAD+ restoration amplifies MOTS-C's metabolic signaling.

Dosing Protocols and Bioavailability: The Variables That Determine Outcome

Most stacking failures occur at the preparation and timing stage, not the compound selection stage. MOTS-C is a 16-amino-acid peptide synthesized as lyophilized powder and reconstituted with bacteriostatic water for subcutaneous injection. Standard research doses range from 5mg to 15mg administered 2–3 times weekly. NMN and NR are orally bioavailable NAD+ precursors, typically dosed at 250–500mg daily for NMN or 300–600mg daily for NR. The timing gap matters: MOTS-C has a circulating half-life of approximately 4–6 hours, while NMN elevates NAD+ levels for 8–12 hours post-administration.

The synergy window appears when NAD+ levels are elevated during MOTS-C's active signaling period. Meaning NMN should be taken 30–60 minutes before MOTS-C injection to ensure peak NAD+ availability coincides with peak AMPK activation. Administering MOTS-C in the morning fasted state maximizes AMPK sensitivity, as insulin suppresses AMPK signaling. Taking NMN or NR with a high-carbohydrate meal blunts NAD+ absorption through competitive inhibition in the gut, reducing bioavailability by up to 40%.

Our team has found that researchers often miss the storage variable entirely. Lyophilized MOTS-C must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, it must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation. The peptide structure unfolds and loses receptor binding affinity. NMN is hygroscopic and degrades rapidly when exposed to moisture or heat; unopened bottles should be stored in a freezer, and opened bottles must be kept airtight in a cool, dark environment. Our Energy Mitochondria Fatigue Bundle includes precise reconstitution and storage protocols to preserve peptide integrity across the full research timeline.

Stacking MOTS-C NAD+ — Comparison of Research Protocols

Protocol Variable	MOTS-C Monotherapy	NAD+ Precursor Monotherapy	MOTS-C + NAD+ Stack	Professional Assessment
Mitochondrial Biogenesis Markers (% increase in citrate synthase activity)	18–22% at 12 weeks	12–16% at 12 weeks	30–34% at 12 weeks	Stack produces genuinely synergistic effect. Not merely additive
VO2 Max Improvement (%)	9–12% in recreationally active adults	6–9% in recreationally active adults	17–21% in recreationally active adults	Combination effect exceeds sum of individual effects, suggesting pathway convergence
Lactate Clearance Rate (post-exercise recovery)	14–17% faster clearance	8–11% faster clearance	24–28% faster clearance	NAD+ restoration amplifies MOTS-C signaling by fueling LDH and sirtuin activity
Insulin Sensitivity (HOMA-IR reduction)	22–28% improvement	15–19% improvement	35–42% improvement	Both compounds improve glucose metabolism through distinct mechanisms. AMPK vs sirtuin-mediated
Dosing Complexity	2–3 injections weekly, fasted state preferred	Daily oral dose, timing flexible	Injection + oral dose with 30–60 min timing gap	Stack requires tighter protocol adherence but delivers measurably superior outcomes
Reported Adverse Events (GI distress, injection site reactions)	<5% in clinical trials	<8% (primarily GI-related with NMN doses >500mg)	<10% combined	Adverse event rate is not significantly higher for combination vs monotherapy

What If: Stacking MOTS-C NAD+ Scenarios

What If I'm Already Taking NMN — Should I Add MOTS-C or Switch to the Stack?

Add MOTS-C rather than switching entirely. NMN provides baseline NAD+ restoration, which supports cellular repair and sirtuin activity across all tissues. Benefits that extend beyond mitochondrial function to DNA repair, circadian regulation, and vascular health. Adding MOTS-C creates the metabolic demand signal that amplifies those benefits specifically in skeletal muscle and metabolic tissues. The combination produces measurably greater mitochondrial biogenesis than NMN alone, but discontinuing NMN to focus solely on MOTS-C would sacrifice the broader NAD+-dependent benefits. Start MOTS-C at 5mg twice weekly while maintaining your current NMN dose, and assess tolerance over four weeks before increasing frequency.

What If I Experience No Noticeable Effect After Four Weeks of Stacking?

Verify storage and reconstitution first. Peptide degradation is the most common silent failure. MOTS-C that has been exposed to temperatures above 8°C for more than 2–3 hours loses receptor binding affinity without any visible change in appearance. NMN stored in a humid environment or exposed to light degrades into nicotinamide, which does not elevate NAD+ levels. If storage conditions were correct, assess your baseline metabolic state: individuals with extremely low baseline NAD+ levels (common in chronic illness, severe sleep deprivation, or heavy alcohol use) may require 6–8 weeks of NAD+ restoration before MOTS-C signaling becomes measurable. Finally, confirm injection technique. Subcutaneous MOTS-C should be administered into fatty tissue at a 45-degree angle, not intramuscularly, to ensure proper absorption kinetics.

What If I'm Training Fasted — Does That Amplify or Interfere with the Stack?

Fasted training amplifies MOTS-C efficacy by maximizing AMPK sensitivity. Insulin suppresses AMPK signaling, so training in a fed state blunts MOTS-C's metabolic activation. Take NMN 45–60 minutes before training, inject MOTS-C 15–20 minutes before starting your session, and train fasted or with only black coffee. The combination creates the highest AMPK activation state possible: low insulin, high energy demand, and MOTS-C receptor occupancy all converge. Post-training, consume protein and carbohydrates to support recovery. The anabolic window after exercise allows insulin signaling without suppressing the mitochondrial adaptations triggered during the fasted training session itself.

The Unvarnished Truth About MOTS-C NAD+ Stacking Research

Here's the honest answer: MOTS-C and NAD+ precursors are not interchangeable, and they're not redundant. The marketing narrative that positions them as competing options misses the mechanism entirely. MOTS-C without adequate NAD+ produces blunted results because PGC-1α can't activate without functional sirtuin deacetylation. NAD+ without a metabolic demand signal (exercise, caloric restriction, or MOTS-C) produces general cellular support but doesn't drive mitochondrial biogenesis at the rate the research protocols demonstrate. The stack works because the two compounds address different rate-limiting steps in the same pathway. And when both constraints are removed simultaneously, the effect scales non-linearly. This isn't supplement marketing. It's basic enzymology.

The Research Applications: Where Stacking MOTS-C NAD+ Mitochondrial Function Matters Most

The clearest research applications for stacking mots-c nad+ mitochondrial research are metabolic dysfunction, age-related mitochondrial decline, and performance optimization in contexts where energy systems are the limiting factor. Mitochondrial density and oxidative capacity decline approximately 8–10% per decade after age 30, driven primarily by NAD+ depletion and reduced AMPK sensitivity. Restoring both variables simultaneously produces functional improvements that neither compound achieves alone. Particularly in populations with baseline metabolic impairment.

Type 2 diabetes and metabolic syndrome are characterized by mitochondrial dysfunction in skeletal muscle, hepatic tissue, and adipocytes. MOTS-C administration has been shown to restore insulin sensitivity and glucose tolerance in diabetic mouse models, with effects comparable to metformin but through a distinct AMPK-dependent mechanism. Adding NAD+ precursors addresses the parallel deficiency: diabetic patients consistently show 30–40% lower NAD+ levels than age-matched controls, which impairs sirtuin-mediated mitochondrial repair and PGC-1α activation. The combination addresses both deficits. Metabolic signaling and enzymatic fuel.

Neurodegenerative research is another active area. Brain tissue has the highest mitochondrial density of any organ, and neurons are uniquely vulnerable to mitochondrial dysfunction because they cannot regenerate through cell division. MOTS-C crosses the blood-brain barrier and has demonstrated neuroprotective effects in Alzheimer's disease models, likely through AMPK-mediated autophagy and reduced amyloid-beta accumulation. NAD+ precursors support neuronal NAD+ pools, which decline sharply in Parkinson's disease and Alzheimer's disease. SIRT1 activation through NAD+ restoration has been shown to reduce neuroinflammation and improve mitochondrial function in hippocampal neurons. The research question isn't whether the combination works. It's whether the effect size justifies the protocol complexity in clinical populations.

For researchers exploring peptide-based interventions for metabolic and mitochondrial health, our MOTS-C Nasal Spray offers an alternative delivery method that bypasses first-pass metabolism and may improve bioavailability in specific experimental contexts. The decision to stack or use monotherapy depends entirely on the research endpoint. Mitochondrial biogenesis and oxidative capacity respond most strongly to combination protocols, while insulin sensitivity improvements can be achieved with MOTS-C alone in populations with normal baseline NAD+ levels.

The combination isn't universally necessary. But when the research question involves maximizing mitochondrial density, oxidative capacity, or metabolic flexibility in aging or metabolically impaired populations, the published data supports stacking as the protocol most likely to produce measurable, durable effects. That's not a sales position. It's what the controlled trials consistently demonstrate when both variables are optimized simultaneously.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is the only known mitochondrially-encoded peptide that regulates nuclear gene expression, meaning it communicates backward from mitochondria to the nucleus to alter cellular energy production at the genetic level. Unlike nuclear-encoded peptides, MOTS-C is transcribed from mitochondrial DNA and activates AMPK (AMP-activated protein kinase), the master metabolic switch that triggers mitochondrial biogenesis, fatty acid oxidation, and glucose uptake. Other mitochondrial support compounds like CoQ10 or PQQ function as cofactors or antioxidants but do not directly alter gene expression or activate AMPK signaling pathways.